Plasmagen Biosciences Private Limited has announced the launch of Haemocomplettan® P (Human Fibrinogen Concentrate), produced by CSL Behring, a business unit of global biotechnology leader CSL. Plasmagen is the exclusive distributor of Haemocomplettan® P in India. This product is approved for the therapy and prophylaxis of hemorrhagic diatheses in congenital afibrinogenemia and acquired hypofibrinogenemia.
India faces a significant burden of uncontrolled massive bleeding during cardiac and liver transplant surgeries, creating a substantial need for products like Haemocomplettan® P. With approximately 150,000 cardiac surgeries and around 1,800 liver transplants performed annually in India, the demand for such therapies is considerable. Nearly half of cardiac surgery patients require blood transfusions to manage hemorrhage, and over 25% of blood transfusions in hospitals are for liver transplant recipients. Haemocomplettan® P is particularly useful in managing massive hemorrhagic cases.
Delayed control of severe bleeding during cardiac surgery can lead to irreversible end-organ damage, including renal failure, strokes, myocardial injury, and even death, significantly increasing healthcare costs. In liver transplants, massive bleeding and excessive blood transfusions can result in prolonged ICU/hospital stays, increased septic episodes, and higher mortality rates. Fibrinogen rapidly restores hemostasis by providing convenient replacement therapy for patients with massive bleeding and fibrinogen deficiency. CSL Behring’s Haemocomplettan® P has over 27 years of experience and has treated over 350,000 patients worldwide.
Dr. N Kanagarajan, Senior Consultant Cardiac Anaesthesiologist at the Madras Medical Mission, Chennai, emphasized fibrinogen’s critical role in managing bleeding during cardiac surgeries, noting its efficacy in restoring fibrinogen levels and reducing intraoperative blood transfusions.
Vinod Nahar, Managing Director of Plasmagen Biosciences, highlighted that the collaboration with CSL Behring will open new avenues in various specialties, including Cardiac, Liver Transplant, Gastroenterology, and Pediatrics. He emphasized the commitment to providing access to quality products with global safety standards and offering holistic solutions in therapy shaping, disease awareness, and patient education.